This content is in French.
Liver, sugar, and pills: who's in control?
4 février 2026
By Ana Espino | Published on February 4, 2026 | 3 min readMASLD (Metabolic dysfunction-associated steatotic liver disease) refers to the accumulation of fat in the liver associated with metabolic syndrome. It is now recognized as one of the main comorbidities of type 2 diabetes (T2D). Its prevalence reaches nearly 70% in diabetic patients, increasing the risk of progression to fibrosis, cirrhosis,
By Ana Espino | Published on February 4, 2026 | 3 min read
MASLD (Metabolic dysfunction-associated steatotic liver disease) refers to the accumulation of fat in the liver associated with metabolic syndrome. It is now recognized as one of the main comorbidities of type 2 diabetes (T2D). Its prevalence reaches nearly 70% in diabetic patients, increasing the risk of progression to fibrosis, cirrhosis, and hepatocellular carcinoma.
Despite this strong association, no validated specific treatment for MASLD currently exists. Current strategies rely on weight loss and glycemic control. Some antidiabetic drugs, such as glitazones or SGLT2 inhibitors, have shown benefits on liver parameters, but the evidence remains inconsistent, mostly derived from isolated trials with heterogeneous endpoints. Moreover, no clear consensus exists regarding the optimal antidiabetic choice in the presence of MASLD, making clinical decision-making challenging.
MASLD (Metabolic dysfunction-associated steatotic liver disease) refers to the accumulation of fat in the liver associated with metabolic syndrome. It is now recognized as one of the main comorbidities of type 2 diabetes (T2D). Its prevalence reaches nearly 70% in diabetic patients, increasing the risk of progression to fibrosis, cirrhosis, and hepatocellular carcinoma.
Despite this strong association, no validated specific treatment for MASLD currently exists. Current strategies rely on weight loss and glycemic control. Some antidiabetic drugs, such as glitazones or SGLT2 inhibitors, have shown benefits on liver parameters, but the evidence remains inconsistent, mostly derived from isolated trials with heterogeneous endpoints. Moreover, no clear consensus exists regarding the optimal antidiabetic choice in the presence of MASLD, making clinical decision-making challenging.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Shao X, et al. Comparison of the efficacy of antidiabetic agents in type 2 diabetes with MASLD: a network meta-analysis. Front Endocrinol (Lausanne). 2026 Jan 7;16:1659740
View the source
